Comparison of Standard vs. Accelerated Corneal Crosslinking

Part of paid clinical trials in Indianapolis, Indiana.

Sponsor
Price Vision Group
Study ID
NCT03922542
Phase
PHASE2/PHASE3
Status
Recruiting
Apply to this trial

Conditions

  • Ectasia Corneal
  • Keratoconus

Eligibility Criteria

Sex
ALL
Age
10 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • riboflavin 0.1% — COMBINATION_PRODUCT
    Use of riboflavin 0.1% eye drops and 9 mW/cm2 UVA light for 10 minutes
  • Riboflavin 0.1% — COMBINATION_PRODUCT
    Use of riboflavin 0.1% eye drops and 3 mW/cm2 UVA light for 30 minutes

Study Details

The study objective is to compare accelerated and standard corneal crosslinking for treatment of progressive keratoconus or corneal ectasia.

Key Dates

Start date
Apr 16, 2019
Status verified
Jul 2025
Primary completion
Jun 1, 2026
Completion
Jul 1, 2026

Study Design

Enrollment
510 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: Accelerated
    Treatment with 0.1% riboflavin eye drops and 9 mW/cm2 UVA light for 10 minutes
  • Active Comparator: Standard
    Treatment with 0.1% riboflavin eye drops and 3 mW/cm2 UVA light for 30 minutes

Primary Outcome Measure

Change in maximum keratometry [ Time Frame: 6 months ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Price Vision GroupIndianapolisIndiana46260
Marianne Price, Ph.D
[email protected]
317-814-2990
Francis Price, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Indianapolis, IN

By research site
Price Vision Group· Indianapolis, IN

Related Studies